Anemia in Patients with Severe Aortic Stenosis

Kazuya Nagao1, Tomohiko Taniguchi2, Takeshi Morimoto3, Hiroki Shiomi3, Kenji Ando4, Norio Kanamori5, Koichiro Murata6, Takeshi Kitai7, Yuichi Kawase8, Chisato Izumi9, Makoto Miyake10, Hirokazu Mitsuoka10, Masashi Kato10, Yutaka Hirano10, Shintaro Matsuda11, Tsukasa Inada12, Tomoyuki Murakami13, Yasuyo Takeuchi14, Keiichiro Yamane15, Mamoru Toyofuku16, Mitsuru Ishii17, Eri Minamino-Muta18, Takao Kato18, Moriki Inoko18, Tomoyuki Ikeda19, Akihiro Komasa19, Katsuhisa Ishii20, Kozo Hotta21, Nobuya Higashitani22, Yoshihiro Kato23, Yasutaka Inuzuka24, Chiyo Maeda25, Toshikazu Jinnai22, Yoko Morikami26, Naritatsu Saito2, Kenji Minatoya27, Takeshi Kimura2 & CURRENT AS Registry Investigators* 

Prognostic impact of anemia complicating severe aortic stenosis (AS) remains unclear. We assessed the impact of anemia on cardiovascular and bleeding outcomes in 3403 patients enrolled in the CURRENT AS registry. 835 patients (25%) had mild (hemoglobin 11.0–12.9 g/dl for men/11.0–11.9 g/dl for women) and 1282 patients (38%) had moderate/severe anemia (Hb ≤ 10.9 g/dl) at diagnosis of severe AS. Mild and moderate/severe anemia were associated with significantly increased risks relative to no anemia (hemoglobin >13.0 g/dl for men ≤12.0 g/dl for women) for the primary outcome measure (aortic valve-related death or heart failure hospitalization) in the entire population [hazard ratio (HR): 1.30; 95% confidence interval (CI): 1.07–1.57 and HR: 1.56; 95% CI: 1.31–1.87, respectively] and in the conservative management stratum (HR: 1.73; 95% CI: 1.40–2.13 and HR: 2.05; 95% CI: 1.69–2.47, respectively). Even in the initial aortic valve replacement stratum, moderate/severe anemia was associated with significantly increased risk for the primary outcome measure (HR: 2.12; 95% CI: 1.44–3.11). Moreover, moderate/severe anemia was associated with significantly increased risk for major bleeding while under conservative management (HR: 1.93; 95% CI: 1.21–3.06). These results warrant further study to explore whether better management of anemia would lead to improvement of clinical outcomes.

1Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan. 2Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. 3Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan. 4Department of Cardiology, Kokura Memorial Hospital, Kokura, Japan. 5Division of Cardiology, Shimada Municipal Hospital, Shimada, Japan. 6Department of Cardiology, Shizuoka City Shizuoka Hospital, Shizuoka, Japan. 7Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan. 8Department of Cardiovascular Medicine, Kurashiki Central Hospital, Kurashiki, Japan. 9Department of Cardiology, Tenri Hospital, Tenri, Japan. 10Division of Cardiology, Nara Hospital, Kinki University Faculty of Medicine, Ikoma, Japan. 11Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan. 12Department of Cardiology, Kinki University Hospital, Osaka, Japan. 13Department of Cardiology, Koto Memorial Hospital, Higashiomi, Japan. 14Department of Cardiology, Shizuoka General Hospital, Shizuoka, Japan. 15Department of Cardiology, Nishikobe Medical Center, Kobe, Japan. 16Department of Cardiology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan. 17Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan. 18Cardiovascular Center, The Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan. 19Department of Cardiology, Hikone Municipal Hospital, Hikone, Japan. 20Department of Cardiology, Kansai Electric Power Hospital, Osaka, Japan. 21Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan. 22Department of Cardiology, Japanese Red Cross Otsu Hospital, Otsu, Japan. 23Department of Cardiology, Saiseikai Noe Hospital, Osaka, Japan. 24Department of Cardiology, Shiga Medical Center for Adults, Moriyama, Japan. 25Department of Cardiology, Hamamatsu Rosai Hospital, Hamamatsu, Japan. 26Department of Cardiology, Hiraizumi Hospital, Hiraizumi, Japan. 27Department of Cardiovascular Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan. *A comprehensive list of consortium members appears at the end of the paper. Correspondence and requests for materials should be addressed to T.K. (email: taketaka@kuhp.kyoto-u.ac.jp)
Aortic stenosis (AS) is the most common valvular disease with poor prognosis and complex pathophysiology. The majority of patients with AS are elderly with multiple co-morbidities causing poor functional status and prognosis. Aortic valve replacement (AVR), either surgical or via a transcatheter approach, is the only therapeutic option in patients with severe AS, while there is no proven medical therapy for improving the prognosis of severe AS. The identification of modifiable comorbidities might lead to improvement in outcomes for patients with severe AS.

Anemia is common in the elderly population and is potentially treatable. Patients with severe AS are particularly susceptible to anemia, because they frequently are on antiplatelet and/or anticoagulant treatment and often suffer from acquired coagulopathy (von Willebrand syndrome type 2A), leading to an increased risk of bleeding. Because tissue oxygen supply is limited due to decreased cardiac output, the concurrent presence of even a mild degree of anemia may harmfully affect the disease course of severe AS. Importantly, pre-existing anemia at the diagnosis of severe AS might be associated with a higher risk of future bleeding events, because anemia could be the result from a longstanding bleeding tendency.

Several recent studies have focused on the relationship between anemia and severe AS. However, most of those studies included only patients who underwent transcatheter aortic valve implantation (TAVI), and anemia was diagnosed during the periprocedural period. Given a considerable number of patients with severe AS patients who are under medical management or a watchful waiting strategy in daily clinical practice, it would be pertinent to evaluate the prognostic impact of anemia present at the time of severe AS diagnosis.

Therefore, we comprehensively evaluated the characteristics of severe AS patients with anemia enrolled consecutively in a large Japanese multicenter registry and assessed the impact of anemia on cardiovascular as well as bleeding outcomes.

Methods

Study Population. The study design and primary results of the CURRENT AS (Contemporary Outcomes After Surgery and Medical Treatment in Patients with Severe Aortic Stenosis) registry have been previously reported. Briefly, the CURRENT AS registry is a retrospective, multicenter registry that enrolled consecutive patients who met the definition of severe AS (i.e. peak aortic jet velocity $V_{\text{max}} > 4.0 \, \text{m/s}$, mean aortic pressure gradient $\text{PG} > 40 \, \text{mmHg}$, or aortic valve area $\text{AVA} < 1.0 \, \text{cm}^2$) for the first time between January 2003 and December 2011 at 27 centers in Japan. The institutional review board or ethics committee at all 27 participating centers approved the study protocol. Written informed consent was waived by all review boards/ethics committees, because we retrospectively gathered the data obtained in the routine clinical practice, and no patient refused to participate in the study when contacted for follow-up. The study was performed in accordance with the relevant guidelines and regulations.

The current study population consisted of 3403 patients with severe AS after excluding 412 patients whose baseline hemoglobin (Hb) values were not available. The study patients were categorized into 3 groups based on the baseline Hb values according to the standard World Health Organization classification of anemia: no anemia (Hb $\geq 13.0 \, \text{g/dl}$ for men, and $\geq 12.0 \, \text{g/dl}$ for women), mild anemia (Hb 11.0–12.9 g/dl for men, and 11.0–11.9 g/dl for women), and moderate/severe anemia (Hb $< 10.9 \, \text{g/dl}$). The median time between the index echocardiography and baseline blood test was 1 day (interquartile range [IQR], 0–10 days).

Follow-up was commenced on the day of the index echocardiography. Follow-up information was collected primarily through review of hospital charts, and additional information was collected from patients, relatives and/or referring physicians via a mailed questionnaire regarding survival, symptoms and subsequent hospitalizations.

Definitions of the Clinical Outcome Measures. The primary outcome measure in the present analysis was the AS-related clinical outcome, namely a composite of aortic valve-related death and heart failure (HF) hospitalization. The secondary outcome measures included the individual components of the primary outcome measure as well as all-cause death, cardiovascular death, sudden death, and non-cardiovascular death. Aortic valve-related death included aortic valve procedural death, sudden death, and death due to HF possibly related to AS. Causes of death were defined according to the Valve Academic Research Consortium (VARC) criteria. HF hospitalization was defined as hospitalization due to deteriorating HF that required intravenous drug therapy. The severity of bleeding events was classified by using Bleeding Academic Research Consortium (BARC) types in accordance with the VARC-2 criteria; major and life-threatening/disabling bleeding in the present study was defined as BARC type 3, and type 5 (Supplementary Data). Other definitions of clinical events have been described previously.

A clinical event committee adjudicated all the clinical events (Supplementary Data).

Statistical Analysis. We compared the baseline characteristics among the 3 groups categorized based on the status of anemia, and explored the independent factors associated with anemia. We also evaluated the prognostic impact of anemia, including stratified analyses according to the initial treatment strategies such as initial AVR and conservative strategies.

Categorical variables are presented as numbers and percentages; these were compared with the chi-square test or Fisher’s exact test. Continuous variables are expressed as the mean and standard deviation or median and IQR. For comparisons across the 3 groups of anemia status, we used analysis of variance or Kruskal-Wallis test.

We explored the factors associated with the presence of mild or moderate/severe anemia by the univariate and multivariable logistic regression models. We simultaneously included the 17 clinically relevant variables listed in Supplementary Table S1 as well as anemia (both mild and moderate/severe) in the model. Continuous variables were dichotomized according to the median value or a clinically meaningful reference value.

The cumulative incidences of the clinical events were estimated by the Kaplan–Meier method, and differences across the 3 groups were assessed with the log-rank test. The risks of mild anemia and moderate/severe anemia, respectively, relative to no anemia (reference) for the primary and secondary outcome measures were
estimated by the Cox proportional hazard models and expressed as hazard ratios (HRs) and their 95% confidence intervals (CIs). We used the dummy code for mild anemia and moderate/severe anemia to estimate the HRs relative to no anemia in the models. Consistent with our previous report, the 22 clinically relevant factors listed in Supplementary Tables S2 and S3 were included as the risk-adjusting variables and the centers were incorporated as the stratification variable in the multivariable Cox proportional hazard models in the entire cohort. Except for age, continuous variables were dichotomized by median or clinically meaningful reference values. We also performed subgroup analyses stratified by clinically relevant factors, such as the initial treatment strategy (initial AVR and conservative), age, symptomatic status, severity of AS, left ventricular systolic function, and renal function. In the subgroup analysis stratified by the initial therapeutic strategy, we constructed parsimonious models with the 6 clinically most relevant risk-adjusting variables listed in Supplementary Tables S2 and S3, because of the small number of patients with outcome. Other than that, the same 22 risk-adjusting variables used in the entire cohort were included in the multivariable Cox proportional hazard models in the subgroup analyses. For those outcome measures with small numbers of patients with events such as sudden death and non-cardiovascular death, multivariable analysis was not performed. We conducted the interaction analyses using a Cox model containing interactive variables (a subgroup term, anemia term and anemia-by-subgroup term) and risk-adjusting variables. Global P for anemia-by-subgroup term was calculated as P for interaction. For the evaluation of bleeding events, we censored patients at the time of AVR/TAVI, because we did not collect data on bleeding and transfusion in the perioperative period. Therefore, we estimated the incidences of the bleeding events specifically while under medical therapy. In the adjusted analyses on the risks of each anemia group for major bleeding events, the same 22 factors as those included in the main analyses were incorporated into multivariable Cox proportional hazard models as the risk-adjusting variables and the centers were incorporated as the stratification variable.

As a sensitivity analysis, the risks of the mild and moderate/severe anemia relative to the no anemia for the primary outcome measure and bleeding events were estimated by the Cox proportional hazard models accounting for the competing risk of AVR/TAVI by using the Gray method.

All statistical analyses were performed with the statistical software program JMP 10.0.0 (SAS Institute Inc., Cary, NC, USA) and SAS 9.4 (SAS Institute Inc., Cary, NC, USA). All reported P values are two-tailed. P values < 0.05 were considered statistically significant.

Results

Baseline Characteristics According to the Severity of Anemia. A large proportion of patients in the present study had anemia; there were 1286 patients (38%) without anemia, and 2117 patients (62%) with anemia, of whom 835 (25%) had mild anemia and 1282 (38%) had moderate/severe anemia (Fig. 1A,B). Median Hb values were 13.4 (IQR: 12.7–14.2) g/dl, 11.6 (11.3–11.9) g/dl, and 9.7 (8.7–10.4) g/dl in the no anemia, mild anemia, and moderate/severe anemia groups, respectively (P < 0.001). Baseline characteristics differed significantly across the 3 groups (Table 1). Overall, patients with moderate/severe anemia were older, more likely to be female, had lower body mass index (BMI), were less likely to have dyslipidemia and more often had a history of HF or malignancy than those with no or mild anemia (Table 1). Patients in the 2 anemia groups more often had a history of percutaneous coronary intervention or coronary artery bypass graft and history of aortic/peripheral vascular diseases than those without anemia. Serum creatinine, brain-derived natriuretic peptide (BNP), C-reactive protein (CRP) and surgical risk scores were higher with increasing severity of anemia (Table 1). Regarding the echocardiographic parameters, compared with patients with no or mild anemia, those with moderate/severe anemia had lower Vmax, smaller AV A, lower left ventricular ejection fraction, thinner wall thickness and greater tricuspid regurgitation PG (Table 1). Proportion of patients with low gradient severe AS (Vmax ≤ 4 m/s and mean aortic PG ≤ 40 mmHg, but AVA < 1.0 cm²) was higher in the patients with moderate/severe anemia as compared with those with no or mild anemia. An initial AVR strategy was selected in 1178 patients (35% of the cohort), of whom 1156 (98.1%) actually underwent surgical AVR (n = 1145) or TAVI (n = 11) at a median interval of 36 (IQR: 16–60) days from the index echocardiography (Table 1). Among the remaining 2225 patients for whom the conservative strategy was initially selected, 451 (20.3%) eventually underwent surgical AVR (n = 429) or TAVI (n = 23) at a median interval of 756 (IQR: 270–1268) days from the index echocardiography (Table 1). Initial AVR strategy was selected less often, and AVR or TAVI was performed less often as the anemia severity increased (Table 1). Further detailed data on baseline characteristics were provided in Supplemental Table S2.

Factors Associated with Anemia. Variables independently associated with anemia included older age, female gender, lower BMI, coronary artery disease and aortic/peripheral disease, renal failure, prior HF, malignancy, liver cirrhosis, and higher tricuspid regurgitation PG (≥40 mmHg) (Supplementary Table S1).

Primary Outcome Measure According to the Severity of Anemia: Entire Cohort. The cumulative 5-year incidence of the primary outcome measure (a composite of aortic valve-related death and HF hospitalization) increased with increasing severity of anemia (22%, 34%, and 56% in the no, mild, and moderate/severe anemia groups, respectively; P < 0.001) (Fig. 2A). Even after adjusting for potential confounders, the excess risk of the mild and moderate/severe anemia groups relative to the no anemia group for the primary outcome measure remained significant (HR: 1.30; 95% CI: 1.07–1.57; P = 0.008, and HR: 1.56; 95% CI: 1.31–1.87; P < 0.001, respectively) (Table 2). When we censored the patients at the time of AVR/TAVI to evaluate the impact of anemia while under conservative management, the excess risks of the 2 anemia groups relative to the no anemia group for the primary outcome measure remained significant (adjusted HR: 1.46; 95% CI: 1.17–1.82; P < 0.001, and adjusted HR: 1.69; 95% CI: 1.38–2.07; P < 0.001, respectively).

In the subgroup analyses, there were no significant interactions between the subgroup factors and the effect of anemia on the primary outcome measure except for the subgroups stratified by renal function (Supplementary Fig. S2).
Primary Outcomes Measure According to the Severity of Anemia Stratified by Initial Therapeutic Strategy. In the conservative stratum, the cumulative 5-year incidence of AVR or TAVI decreased with increasing severity of anemia (43%, 37%, and 25%, respectively, P < 0.001), whereas in the initial AVR stratum, the vast majority of patients underwent AVR or TAVI regardless of the severity of anemia (Supplementary Fig. S3A,B). Regardless of the initial treatment strategies (initial AVR and conservative), the effects of anemia severity for the primary outcome measure were generally in the same direction as those in the entire cohort with no positive interaction between anemia severity and the initial therapeutic strategies (interaction P = 0.2) (Table 2), although the outcomes of each anemia group were remarkably better in the AVR than in the conservative stratum (Fig. 2B,C).

Secondary Outcome Measures According to the Severity of Anemia. The effects of the severity of anemia for the secondary outcome measures such as aortic valve-related death, HF hospitalization, all-cause death and cardiovascular death were generally in the same direction as for the primary outcome measure in the entire cohort, and in the conservative stratum (Table 2, and Supplementary Fig. S1). In the initial AVR stratum, moderate/severe anemia as compared with no anemia was associated with significantly higher risk for all the secondary outcome measures, whereas mild anemia as compared with no anemia was associated with significantly higher risk only for all-cause death, cardiovascular death and non-cardiovascular death (Table 2). There were no significant interactions between the initial therapeutic strategies and the effect of anemia on the secondary outcome measures (interaction P = 0.08, 0.7, 0.2 and 0.06 for aortic valve-related death, HF hospitalization, all-cause death and cardiovascular death, respectively).

Figure 1. (A) Histograms of hemoglobin levels. (B) Study flowchart AS = aortic stenosis, AVR = aortic valve replacement.
mia group (adjusted HR: 1.15, 95%CI: 0.69–1.91, P = 0.001). Further detailed data on baseline characteristics were provided in Supplemental Table S2.

The values of CRP and BNP were obtained in 2914 (76%) and 1801 (47%) patients, respectively. Bleeding events were the two main bleeding sites (Fig. 3B). One-third of the bleeding events was major bleeding (BARC type 3a), whereas two-thirds of the bleeding events were life-threatening or disabling bleeding (BARC types 3b, 3c and 5) (Fig. 3C).

### Table 1. Baseline Characteristics According to the Status of Anemia

| Variables | No anemia Hb ≥ 13.0 g/dl for men, and ≥12.0 g/dl for women | Mild anemia Hb 11.0–12.9 g/dl for men, and 11.0–11.9 g/dl for women | Moderate/Severe anemia Hb < 10.9 g/dl | P value |
|-----------|----------------------------------------------------------|---------------------------------------------------------------|-----------------------------------|---------|
| N         | N = 1286                                                 | N = 835                                                       | N = 1282                          |         |
| Age, y    | 74.5 ± 9.9                                               | 78.0 ± 8.7                                                   | 81.4 ± 8.7                        | <0.001  |
| Men       | 524 (41)                                                 | 399 (48)                                                     | 371 (29)                          | <0.001  |
| BMI, kg/m²| 22.7 ± 3.7                                               | 22.0 ± 3.7                                                  | 20.6 ± 3.6                        | <0.001  |
| Hypertension | 879 (68)                                           | 598 (72)                                                     | 923 (72)                          | 0.09    |
| Current smoking | 87 (7)                                           | 51 (6)                                                       | 37 (3)                            | <0.001  |
| Dyslipidemia | 514 (40)                                          | 308 (37)                                                     | 372 (29)                          | <0.001  |
| Diabetes mellitus | 296 (23)                           | 209 (25)                                                     | 323 (25)                          | 0.4     |
| Coronary artery disease | 341 (27)                           | 304 (36)                                                     | 398 (31)                          | <0.001  |
| Prior PCI | 126 (10)                                                  | 132 (16)                                                     | 189 (15)                          | <0.001  |
| Prior CABG | 38 (3)                                                   | 58 (7)                                                       | 72 (6)                            | <0.001  |
| Prior myocardial infarction | 73 (6)                                     | 79 (9)                                                       | 132 (10)                          | <0.001  |
| Prior HF  | 158 (12)                                                  | 119 (14)                                                     | 314 (24)                          | <0.001  |
| Aortic/periappendicular disease | 156 (12)                           | 152 (18)                                                     | 227 (18)                          | <0.001  |
| Serum creatinine, mg/dl | 0.8 (0.6–1.0)                  | 0.9 (0.7–1.2)                                                | 1.1 (0.8–2.3)                     | <0.001  |
| Hemoglobin, g/dl | 13.4 (12.7–14.2)                        | 11.6 (11.3–11.9)                                            | 9.7 (8.7–10.4)                    | <0.001  |
| BNP, pg/ml | 143 (57–432)                                             | 216 (97–615)                                                | 554 (202–1357)                    | <0.001  |
| CRP, mg/dl | 0.13 (0.06–0.36)                                         | 0.2 (0.08–0.64)                                             | 0.43 (0.1–2.2)                    | <0.001  |
| Malignancy | 145 (11)                                                 | 114 (14)                                                     | 216 (17)                          | <0.001  |
| Chronic lung disease | 159 (12)                               | 88 (11)                                                      | 119 (9)                           | 0.04    |
| Logistic EuroSCORE, % | 7.0 (4.2–12.0)                           | 9.4 (6.2–16.0)                                              | 14.2 (9.0–23.0)                   | <0.001  |
| EuroSCORE II, % | 1.9 (1.2–3.5)                        | 2.8 (1.7–4.5)                                                | 4.1 (2.7–6.8)                     | <0.001  |
| STS score (PROM), % | 2.5 (1.6–4.0)                      | 3.8 (2.4–5.9)                                                | 6.1 (3.7–10)                      | <0.001  |

### Echocardiographic variables

| Vmax, m/s | 4.2 ± 0.9 | 4.2 ± 0.9 | 4.1 ± 0.9 | 0.01 |
| Mean aortic PG, mmHg | 42 ± 20 | 42 ± 21 | 41 ± 20 | 0.09 |
| AVA (equation of continuity), cm² | 0.73 ± 0.18 | 0.72 ± 0.18 | 0.69 ± 0.19 | <0.001 |
| Low gradient AS (Vmax ≤ 4 m/s and mean aortic PG < 40 mmHg, but AVA < 1.0 cm²) | 537 (42) | 356 (43) | 597 (47) | 0.04 |
| LVEF, % | 64 ± 13 | 63 ± 13 | 61 ± 14 | <0.001 |
| IVST in diastole, mm | 11.5 ± 2.4 | 11.5 ± 2.3 | 11.2 ± 2.2 | 0.002 |
| PWT in diastole, mm | 11.1 ± 2.0 | 11.1 ± 2.2 | 10.9 ± 2.0 | 0.04 |
| TR pressure gradient ≥40 mm Hg | 158 (12) | 117 (14) | 292 (23) | <0.001 |

### Therapeutic strategy

| Initial AVR | 549 (43) | 316 (38) | 313 (24) | <0.001 |
| Conservative | 737 (57) | 519 (62) | 969 (76) | <0.001 |

**Bleeding Events Under Conservative Management.** In the entire cohort, 152 (4.5%) patients had major of life-threatening bleeding events while under conservative management. The cumulative 5-year incidence of bleeding events was incrementally higher with the increasing severity of anemia (7%, 12%, and 18%, respectively, P < 0.001) (Fig. 3A). After adjusting for the potential confounders, the excess risk of the moderate/severe anemia group relative to the no anemia group remained highly significant (HR: 1.93; 95%CI: 1.21–3.06; P = 0.005), whereas no significant increased risk was observed for the mild anemia group relative to the no anemia group (adjusted HR: 1.15, 95%CI: 0.69–1.91, P = 0.6). Gastrointestinal (55%) and intracranial bleeding (22%) were the two main bleeding sites (Fig. 3B). One-third of the bleeding events was major bleeding (BARC type 3a), whereas two-thirds of the bleeding events were life-threatening or disabling bleeding (BARC types 3b, 3c and 5) (Fig. 3C).
Sensitivity analysis for the excess risk of anemia accounting for the competing risk of AVR/TAVI. Sensitivity analysis confirmed that even when the competing risk of AVR/TAVI was accounted for, the excess risks relative to the no anemia group for the primary outcome measure remained significant in both the mild (unadjusted HR: 1.75; 95% CI: 1.43–2.15; P < 0.001, adjusted HR: 1.43; 95% CI: 1.15–1.77; P = 0.001) and the moderate/severe anemia group (unadjusted HR: 3.45; 95% CI: 2.90–4.10; P < 0.001, adjusted HR: 1.60; 95% CI: 1.30–1.96; P < 0.001). Likewise, the adjusted excess risk of the moderate/severe anemia group relative to the no anemia group for the major or life-threatening bleeding events remained highly significant (unadjusted HR: 3.33;
|                  | No anemia | Mild anemia versus No anemia | Moderate/Severe anemia versus No anemia |
|------------------|-----------|-------------------------------|---------------------------------------|
|                  | N of patients | N of patients | Unadjusted HR (95% CI) | P Value | Adjusted HR (95% CI) | P Value | N of patients | Unadjusted HR (95% CI) | P Value | Adjusted HR (95% CI) | P Value |
| Entire Cohort (N = 3403) |           |                   |                        |         |                      |         |              |                        |         |                      |         |
| Primary outcome measure |           |                   |                        |         |                      |         |              |                        |         |                      |         |
| Aortic valve-related death | 209 (22)  | 214 (34)           | 1.71 (1.43–2.05)       | <0.001  | 1.30 (1.07–1.57)     | 0.008   | 482 (56)     | 3.31 (2.83–3.87)       | <0.001  | 1.56 (1.31–1.87)     | <0.001  |
| HF hospitalization | 158 (18)  | 158 (28)           | 1.70 (1.38–2.10)       | <0.001  | 1.39 (1.12–1.73)     | 0.003   | 362 (48)     | 3.44 (2.88–4.12)       | <0.001  | 1.79 (1.46–2.20)     | <0.001  |
| All-cause death | 263 (26)  | 282 (43)           | 1.85 (1.58–2.18)       | <0.001  | 1.20 (1.02–1.42)     | 0.03    | 677 (65)     | 3.73 (3.26–4.28)       | <0.001  | 1.62 (1.39–1.89)     | <0.001  |
| Cardiovascular death | 163 (17)  | 189 (31)           | 1.92 (1.57–2.35)       | <0.001  | 1.24 (1.01–1.52)     | 0.04    | 448 (50)     | 3.92 (3.31–4.65)       | <0.001  | 1.52 (1.25–1.84)     | <0.001  |
| Sudden death | 34 (3)    | 40 (7)             | 1.79 (1.18–2.72)       | 0.007   | 1.03 (0.64–1.57)     | 1.0     | 83 (14)      | 2.95 (2.05–4.26)       | <0.001  | 1.07 (0.69–1.64)     | 0.8     |
| Non-cardiovascular death | 100 (12)  | 93 (17)            | 1.74 (1.33–2.27)       | <0.001  | 1.13 (0.85–1.49)     | 0.4     | 229 (29)     | 3.40 (2.71–4.28)       | <0.001  | 1.83 (1.41–2.38)     | <0.001  |
| Conservative Stratum (N = 2225) |           |                   |                        |         |                      |         |              |                        |         |                      |         |
| Primary outcome measure |           |                   |                        |         |                      |         |              |                        |         |                      |         |
| Aortic valve-related death | 159 (30)  | 177 (47)           | 1.79 (1.46–2.20)       | <0.001  | 1.73 (1.40–2.13)     | <0.001  | 421 (66)     | 3.13 (2.63–3.74)       | <0.001  | 2.05 (1.69–2.47)     | <0.001  |
| HF hospitalization | 129 (26)  | 134 (39)           | 1.71 (1.36–2.16)       | <0.001  | 1.63 (1.28–2.06)     | <0.001  | 329 (59)     | 3.18 (2.62–3.88)       | <0.001  | 2.05 (1.66–2.54)     | <0.001  |
| All-cause death | 207 (36)  | 224 (54)           | 1.79 (1.50–2.15)       | <0.001  | 1.52 (1.26–1.83)     | <0.001  | 586 (72)     | 3.25 (2.8–3.8)         | <0.001  | 2.09 (1.77–2.46)     | <0.001  |
| Cardiovascular death | 125 (23)  | 155 (41)           | 1.94 (1.55–2.43)       | <0.001  | 1.76 (1.40–2.22)     | <0.001  | 387 (58)     | 3.46 (2.86–4.19)       | <0.001  | 2.19 (1.79–2.69)     | <0.001  |
| Sudden death | 25 (4)    | 36 (10)            | 2.01 (1.26–3.21)       | 0.003   | N/A                  | N/A     | 73 (15)      | 2.7 (1.8–4.19)         | <0.001  | N/A                  | N/A     |
| Non-cardiovascular death | 82 (17)   | 69 (21)            | 1.54 (1.13–2.10)       | 0.006   | N/A                  | N/A     | 199 (33)     | 2.92 (2.27–3.78)       | <0.001  | N/A                  | N/A     |
| Initial AVR Stratum (N = 1178) |           |                   |                        |         |                      |         |              |                        |         |                      |         |
| Primary outcome measure |           |                   |                        |         |                      |         |              |                        |         |                      |         |
| Aortic valve-related death and HF hospitalization | 50 (11)   | 37 (15)            | 1.36 (0.90–2.02)       | 0.1     | 1.24 (0.82–1.88)     | 0.3     | 61 (29)      | 2.47 (1.73–3.54)       | <0.001  | 2.12 (1.44–3.11)     | <0.001  |
| HF hospitalization | 29 (7)    | 24 (11)            | 1.5 (0.91–2.45)        | 0.1     | 1.30 (0.77–2.19)     | 0.3     | 33 (22)      | 2.33 (1.46–3.71)       | 0.002   | 1.79 (1.08–2.97)     | 0.02    |
| All-cause death | 56 (13)   | 58 (25)            | 1.89 (1.34–2.67)       | <0.001  | 1.88 (1.31–2.69)     | <0.001  | 91 (42)      | 3.66 (2.69–5.02)       | <0.001  | 3.62 (2.57–5.08)     | <0.001  |
| Cardiovascular death | 38 (9)    | 34 (15)            | 1.66 (1.06–2.58)       | 0.03    | 1.70 (1.07–2.68)     | 0.02    | 61 (29)      | 3.81 (2.61–5.63)       | <0.001  | 3.94 (2.60–5.95)     | <0.001  |
| Sudden death | 9 (2)     | 4 (2)              | 0.86 (0.27–2.38)       | 0.8     | N/A                  | N/A     | 11 (10)      | 2.37 (1.01–5.57)       | 0.03    | N/A                  | N/A     |
| Non-cardiovascular death | 18 (5)    | 24 (12)            | 2.34 (1.34–4.12)       | 0.005   | N/A                  | N/A     | 30 (16)      | 3.36 (1.97–5.83)       | <0.001  | N/A                  | N/A     |

Table 2. Crude and Adjusted Effects of Anemia for Clinical Outcomes. AVR = aortic valve replacement; CI = confidence interval; HF = heart failure; HR = hazard ratio.

95% CI: 2.24–4.94; P < 0.001, adjusted HR: 1.92; 95% CI: 1.24–2.99; P = 0.004 even when the competing risk of AVR/TAVI was accounted for, whereas no significant excess risk relative to the no anemia group was observed in the mild anemia group (unadjusted HR: 1.57; 95%CI: 0.97–2.53, P = 0.07, adjusted HR: 1.92; 95% CI: 1.24–2.99; P = 0.004).
Discussion

In a large cohort of patients with severe AS, we found that more than 60% of patients had anemia at the time of severe AS diagnosis. Moderate/severe anemia was associated with extremely worse prognosis with increased risk for AS-related adverse events regardless of the therapeutic strategy. Even a mild degree of anemia was associated

Figure 3. Relationship between anemia and bleeding events under conservative management. (A) Kaplan–Meier curves for major or life-threatening bleeding events under conservative management in the entire cohort. (B,C) Sites (B) and severity (C) of bleeding under conservative management in the entire cohort of bleeding. Cumulative incidence of major or life-threatening/disabling bleeding events under conservative management was estimated by the Kaplan–Meier method with censoring at AVR/TAVI. AVR = aortic valve replacement, BARC = Bleeding Academic Research Consortium, and TAVI = transcatheter aortic valve implantation.
with significantly worse prognosis in the entire population and in the patients who were medically managed. Furthermore, moderate/severe anemia was associated with increased risk of major or life-threatening bleeding while under medical therapy.

Previous reports are limited for the prognostic impact of Hb levels at severe AS diagnosis. In one study exploring the relationship between baseline anemia and prognosis in 856 AS patients, the prevalence of anemia increased with increasing severity of AS, and anemia was independently associated with increased all-cause mortality while under medical therapy, but not after AVR surgery. Of note, the patients included in that study were much younger (mean age, 71 years) than those in our study and had less severe AS, with more than 50% of their patients having moderate AS. This may be related to a much lower prevalence of anemia in their cohort (32%) as compared with ours (63%). In other cohorts including the patients who underwent TAVI, the prevalence of preoperative anemia was 45–64%. We found several predisposing factors to anemia such as older age, low BMI, a history of HF, coronary artery disease and aortic/peripheral disease, renal failure and malignancy. The results may reflect the growing prevalence of severe AS in the elderly population with multiple comorbidities, and all these factors may synergistically contribute to the extremely poor prognosis in severe AS patients associated with anemia. Particularly, end-stage renal function deleteriously affects the prognosis of severe AS, as reported in our previous study. Nevertheless, even after careful adjustment for a broad array of baseline characteristics including renal function, we still found anemia to be a strong indicator of poor prognosis. AVR/TAVI strategy was selected less often in patients with higher-grade anemia, which might have increased the rate of clinical events in the entire cohort. However, even in the initial AVR stratum in which more than 98% of the patients underwent AVR, the cumulative 5-year incidence of the primary outcome measure still was incrementally higher with increasing severity of anemia. Furthermore, even a mild degree of anemia was associated with significantly worse outcomes; its deleterious effect was prominent in those patients with advanced age, without symptoms, without ‘very severe’ AS (Vmax < 5 m/s) and with preserved left ventricular systolic function (ejection fraction ≥50%). Notably, these factors might predispose to the selection of conservative strategy rather than initial AVR strategy. Importantly, in contrast to the previous reports from TAVI cohorts, our study enrolled consecutive patients with severe AS, and therefore, included substantial proportion of patients who were managed conservatively. Negative prognostic impact of anemia was more prominent in patients with a conservative strategy than in those with an initial AVR strategy. Given these results, together with lack of effective medical management for severe AS, anemia might be an important target of medical management in patients with severe AS. For example, iron therapy, which has been proven for improving the functional status of chronic HF patients, might be a viable therapeutic option for patients with severe AS, which should be evaluated in prospective studies.

We found that the patients with baseline anemia had an elevated risk of major or life-threatening bleeding events as compared with those without anemia. Similarly, Philippe et al. reported that the presence of low Hb levels at baseline was significantly associated with major bleeding complications within 30 days of surgical AVR. The presence of anemia at severe AS diagnosis could be the result from longstanding bleeding tendency, possibly due to the continuous prescription of antithrombotic drugs, or von Willebrand syndrome type 2A. Importantly, the presence of anemia at the diagnosis of severe AS often might be regarded as ‘not severe’, especially in elderly patients. However, given the highly significant association between the presence of anemia and the extremely poor prognosis demonstrated in our study, we might have need to pay more attention to anemia in patients with severe AS.

Limitations. This study had several limitations. First, anemia was evaluated only at baseline. Therefore, the subsequent change in Hb and its relationship with the prognosis remains unclear. Second, the relationship between baseline anemia and the incidence of AVR/TAVI-related bleeding events remains unclear, because our study focused more on the bleeding events under conservative management rather than on procedure-related events. Third, to keep consistency with our previous reports, the same clinically relevant factors as in our previous reports were included as the risk-adjusting variables in the Cox proportional hazard models. However, this strategy might result in overfitting models particularly in the analyses for some secondary outcomes and bleeding events. Fourth, patients with anemia were more likely to be frail, have a history of HF, malignancy and coronary artery or aortic/peripheral disease than those without anemia. In addition, they were more likely to have higher BNP, CRP and surgical risk scores. Despite an extensive statistical adjustment for potential confounders obtained in our registry, we cannot deny the residual unmeasured confounders such as frailty. Finally, it should be acknowledged that the CURRENT AS registry included mostly Asian patients and, hence, limits the generalizability of the study to mostly Asian patients with AS.

Conclusions
Anemia is a common comorbidity in patients with severe AS and is associated with worse cardiovascular as well as bleeding outcomes. Further study should be warranted to explore whether better management of anemia would lead to improvement of clinical outcomes.

References
1. Nkomo, V. T. et al. Burden of valvular heart diseases: a population-based study. Lancet 368, 1005–11 (2006).
2. Otto, C. M. Valvular aortic stenosis: disease severity and timing of intervention. J Am Coll Cardiol 47, 2141–51 (2006).
3. Osnabrugge, R. L. et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll Cardiol 62, 1002–12 (2013).
4. Marquis-Gravel, G., Redfors, B., Leon, M. B. & Generoux, P. Medical treatment of aortic stenosis. Circulation 134, 1766–1784 (2016).
5. Stauder, R., Valentin, P. & Theurl, I. Anemia at older age: etiologies, clinical implications, and management. Blood 131, 505–514 (2018).
6. Strotecky, S. et al. Validation of the Valve Academic Research Consortium bleeding definition in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. J Am Heart Assoc 4, e002135 (2015).
7. Vincentelli, A. et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 349, 343–9 (2003).
8. Nuis, R. J. et al. Prevalence, factors associated with, and prognostic effects of preoperative anemia on short- and long-term mortality in patients undergoing transcatheter aortic valve implantation. Circ Cardiovasc Inter 6, 625–34 (2013).
9. Ng, A. C. et al. Anemia in patients with aortic stenosis: influence on long-term prognosis. Eur J Heart Fail 17, 1042–9 (2015).
10. Delarochelliere, H. et al. Effect on outcomes and exercise performance of anemia in patients with aortic stenosis who underwent transcatheter aortic valve replacement. Am J Cardiol 115, 472–9 (2015).
11. Arai, T. et al. Impact of pre- and post-procedural anemia on the incidence of acute kidney injury and 1-year mortality in patients undergoing transcatheter aortic valve implantation (from the French Aortic National CoreValve and Edwards 2 [FRANCE 2] Registry). Catheter Cardiovasc Interv 85, 1231–9 (2015).
12. Martinez-Selles, M. et al. Prospective registry of symptomatic severe aortic stenosis in octogenarians: a need for intervention. J Intern Med 275, 608–20 (2014).
13. Taniguchi, T. et al. Initial surgical versus conservative strategies in patients with asymptomatic severe aortic stenosis. J Am Coll Cardiol 66, 2827–38 (2015).
14. Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser 405, 5–37 (1968).
15. Anker, S. D. et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol 57, 253–69 (2011).
16. Kappetein, A. P. et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol 60, 1438–54 (2012).
17. Mehran, R. et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123, 2736–47 (2011).
18. Barraclough, H. & Govindan, R. Biostatistics primer: what a clinician ought to know: subgroup analyses. J Thorac Oncol 5, 741–6 (2010).
19. Fine, J. P. & Gray, R. J. A Proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association 84, 425–45 (1989).
20. Ribeiro, T. et al. Prognostic impact of anemia and iron-deficiency anemia in a contemporary cohort of patients undergoing transcatheter aortic valve implantation. Int J Cardiol 244, 93–99 (2017).
21. Van Mieghem, N. M. et al. Prevalence and prognostic implications of baseline anemia in patients undergoing transcatheter aortic valve implantation. EuroIntervention 7, 184–91 (2011).
22. Kawase, Y. et al. Severe aortic stenosis in dialysis patients. J Am Heart Assoc 6 (2017).
23. Nishimura, R. A. et al. AHA/ACC Guideline for the management of patients with valvular heart disease; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129, e521–643 (2014).
24. Genereux, P. et al. Natural history, diagnostic approaches, and therapeutic strategies for patients with asymptomatic severe aortic stenosis. J Am Coll Cardiol 67, 2263–88 (2016).
25. Vahanian, A. et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 33, 2451–96 (2012).
26. Anker, S. D. et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361, 2436–48 (2009).
27. Picard, R. M. et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 36, 657–68 (2015).
28. Genereux, P. et al. Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement. J Am Coll Cardiol 64, 2605–15 (2014).
29. Warkentin, T. E., Moore, J. C. & Morgan, D. G. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand’s disease the link? Lancet 340, 35–7 (1992).
30. Afilalo, J. et al. Frailty in older adults undergoing aortic valve replacement: The FRAILTY-AVR Study. J Am Coll Cardiol 70, 689–700 (2017).

Acknowledgements
We thank CURRENT AS Registry Group for its contribution. Research Institute for Production Development (Kyoto, Japan).

Author Contributions
T. Kimura had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: K.N., T.T., T. Kimura. Acquisition, analysis, or interpretation of data: K.N., T.T., T.M., H.S., K.A., K.M., K.R., M.H., M.K., Y.H., M.T., T. Inada, T. Murakami, Y.T., K.Y., M.T., M. Ishii, E.M.-M., T. Kato, M. Inoko, T. Ikeda, A.K., K.I., K.H., N.H., Y. Kato, Y.I., C.M., T.J., Y.M., N.S., K. Minatoya, T. Kimura. Drafting of the manuscript: K.N., T. Kimura.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-36066-z.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019
Consortia
CURRENT AS Registry Investigators

Naoki Takahashi1, Kohei Fukuchi2, Masao Imai2, Junichi Tazaki2, Toshiaki Toyota2, Hirooki Higami2, Tetsuma Kawaji3, Shintichi Shirai4, Kengo Kourai4, Takeshi Arita4, Shiro Miura5, Kyohi Yamaji6, Tomoya Onodera7, Yutaka Furukawa7, Kitae Kim7, Kazushige Kadota8, Keiichiro Iwasaki8, Hiroshi Miyawaki8, Ayumi Misao8, Akimune Kuwayama8, Masanobu Ohya8, Takenobu Shimada8, Hidewo Amano8, Yoshihisa Nakagawa9, Masashi Amano9, Yusuke Takahashi10, Yusuke Yoshikawa10, Shunjuku Nishimura10, Maiko Kuroda10, Manabu Shirotani10, Shinji Miki10, Tetsu Mizoguchi11, Takafumi Yokomatsu11, Akihiro Kushiyama11, Hidenori Yaku11, Toshimitsu Watanabe11, Shinichi Miyazaki12, Teruki Takeda13, Tomoko Sakaguchi13, Keiko Maeda13, Masayuki Yamaji13, Maenaka Motoyoshi13, Yutaka Tadano13, Hiroki Sakamoto14, Makoto Motooka14, Ryusuke Nishikawa14, Hiroshi Eizawa15, Mitsunori Kawato15, Minako Kinoshita15, Kenji Aida15, Takashi Tamura16, Kousuke Takahashi16, Euihong Ko16, Masaharu Akao17, Nobutoyo Masunaga17, Hisashi Ogawa17, Moritake Iguchi17, Takashi Unoki17, Kensuke Takabayashi17, Yasuhiro Hamatani17, Yugo Yamashita17, Yoshihiro Himura18, Yukihiro Sato18, Shuhei Tsuji18, Takashi Konishi18, Kouji Sogabe18, Michiya Tachiiri18, Yukiko Matsumura19, Chihiro Ota19, Ichiro Kouchi20, Shigeru Ikekuchi21, Soji Nishio21, Juunya Seki21, Eiji Shinoda22, Miho Yamada22, Akira Kamoto22, Shoji Kitaguchi22, Ryuzo Sakata22, Mitsuo Matsuda23, Sachiko Sugioka23, Yuji Hiraoka23, Michiya Hanu20, Fumio Yamazaki21, Tadaaki Koyama21, Tatsuhiko Komiyama24, Kazuo Yamanaka25, Noboru Nishiwaki25, Hiroyuki Nakajima26, Motoaki Ohnaka26, Hiroaki Osada26, Katsuki Meshii26, Toshihiko Saga27, Masahiko Onoe28, Shogo Nakayama29, Genichi Sakaguchi30, Atsushi Iwakura31, Kotaro Shiraga32, Koji Ueyama33, Keichi Fujiwara34, Atsushi Fukumoto35, Senri Miwa36, Junichiro Nishizawa37 & Mitsuru Kitano38

20Department of Cardiology, Kishiwada City Hospital, Kishiwada, Japan. 21Department of Cardiology, Rakukwaki Otowa Hospital, Kyoto, Japan. 22Department of Cardiovascular Surgery, Kokura Memorial Hospital, Kitakyushu, Japan. 23Department of Cardiovascular Surgery, Shizuoka City Shizuoka Hospital, Shizuoka, Japan. 24Department of Cardiovascular Surgery, Kobe City Medical Center General Hospital, Kobe, Japan. 25Department of Cardiovascular Surgery, Kurashiki Central Hospital, Kurashiki, Japan. 26Department of Cardiovascular Surgery, Tenri Hospital, Tenri, Japan. 27Department of Cardiovascular Surgery, National Hospital Organization Kyoto Medical Center, Kyoto, Japan. 28Department of Cardiovascular Surgery, Cardiovascular Center, The Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan. 29Department of Cardiovascular Surgery, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan. 30Department of Cardiovascular Surgery, Rakukwaki Otowa Hospital, Kyoto, Japan. 31Department of Cardiovascular Surgery, Shiga Medical Center for Adults, Moriyama, Japan. 32Department of Cardiovascular Surgery, Hamamatsu Rosai Hospital, Hamamatsu, Japan. 33Department of Cardiovascular Surgery, Japanese Red Cross Otsu Hospital, Otsu, Japan.